Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX-322 in Stable Sensorineural Hearing Loss
NCT03616223Phase 2Completed
- Sponsor
- Frequency Therapeutics
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FX-322 in sensorineural hearing loss (SNHL) (4 arms), sponsored by Frequency Therapeutics. Primary endpoint: Treatment-emergent Adverse Events at Day 90. Started Jul 2018; status: completed.
02
Drugs
FX-322
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT03616223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616223.